Skin and wound support: KPV is also discussed for inflammatory skin conditions and tissue repair
The expectation, based on the related semaglutide SELECT trial that showed a 20% reduction in major adverse cardiovascular events in obesity, is that tirzepatide will show similar or larger benefits
From what we see across performance and wellness markets, BPC-157 continues to attract interest precisely because the preclinical biology is compelling, yet human data remains almost entirely anecdotal
however, it is generally safe to supplement with for three to six months
GLOW is not an injury protocol
[1] [2] However, these studies were limited by small sample sizes, short duration, and lack of long-term safety data